



Review

Recent Advances in Flavin-Dependent Halogenase Biocatalysis: Sourcing, Engineering, and Application

Johannes Büchler[†], Athena Papadopoulou[†] and Rebecca Buller *D

Department of Life Sciences and Facility Management, Competence Center for Biocatalysis, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Waedenswil, Switzerland; johannes.buechler@zhaw.ch (J.B.); athena.papadopoulou@zhaw.ch (A.P.)

- * Correspondence: rebecca.buller@zhaw.ch; Tel.: +41-58-934-5438
- † These authors contributed equally.

Received: 15 November 2019; Accepted: 2 December 2019; Published: 5 December 2019



Abstract: The introduction of a halogen atom into a small molecule can effectively modulate its properties, yielding bioactive substances of agrochemical and pharmaceutical interest. Consequently, the development of selective halogenation strategies is of high technological value. Besides chemical methodologies, enzymatic halogenations have received increased interest as they allow the selective installation of halogen atoms in molecular scaffolds of varying complexity under mild reaction conditions. Today, a comprehensive library of aromatic halogenases exists, and enzyme as well as reaction engineering approaches are being explored to broaden this enzyme family's biocatalytic application range. In this review, we highlight recent developments in the sourcing, engineering, and application of flavin-dependent halogenases with a special focus on chemoenzymatic and coupled biosynthetic approaches.

Keywords: flavin-dependent halogenases; enzyme engineering; anion promiscuity; reaction engineering; co-factor recycling; biocatalysis

1. Introduction

In nature, over 5000 halogenated products have been described since their first discovery over 100 years ago including potent antimicrobial agents such as vancomycin and chloramphenicol (Figure 1) [1]. The incorporation of a halogen can significantly alter a molecule's properties and may impact its bioactivity, metabolism, and pharmacokinetic profile [2]. As a consequence, the selective halogenation of small molecules is of great interest in the pharmaceutical and agrochemical industry. Around 20% of small molecule drugs and approximately 30% of agrochemicals are halogenated [3] Examples in the pharmaceutical industry include blockbusters such as rivaroxaban and empagliflozin with annual sales revenues in 2018 of \$6.6 and \$2.3 billion, respectively (Figure 1) [4]. Furthermore, C-X motifs are useful synthetic handles for modification of the molecule in further chemical steps, making halogenated species common intermediates in synthetic manufacturing routes [5,6]. However, chemical halogenation, even though being a well-established technology, suffers from the use of hazardous or even highly toxic chemicals and sometimes poor atom efficiency [7,8]. In addition, chemical methods often lack selectivity or have specific demands on the substrate structure [8,9]. Consequently, the replacement of chemical halogenation by biological means may offer a more selective, greener, and less dangerous process route toward molecules of industrial interest.

Biocatalytic halogenation is carried out by enzymes called halogenases or haloperoxidases, which can be classified according to their catalytic mechanism: heme, vanadium, and flavin-dependent halogenases follow an electrophilic mechanism, while non-heme iron halogenases halogenate through the formation of radical intermediates, and S-adenosyl-L-methionine (SAM) fluorinases react via a

Catalysts 2019, 9, 1030 2 of 20

nucleophilic pathway [10]. This review will focus on work carried out on flavin-dependent halogenases (electrophilic halogenases), which in contrast to heme- and vanadium-dependent halogenases, selectively derivatize small molecules, making them especially interesting for applications.




Figure 1. Selection of valuable halogenated agrochemicals, pharmaceuticals and natural products.

Flavin-dependent halogenases (Fl-Hals) use reduced flavin, bound in the FAD binding site of the enzyme, to create a C4a-hydroperoxyflavin species upon reaction with oxygen [11]. The generated peroxy species cannot react directly with the substrate as the flavin binding site and the substrate binding site are separated by an approximately 10 Å long tunnel [12–15]. Instead, crystal structures of flavin-dependent halogenases show the presence of a chloride binding site near the flavin binding site [15,16], and mechanistic studies suggest that a nucleophilic attack of the chloride on the peroxyflavin may create hypohalous acid (HOX) [11]. The hypohalous acid then travels to the substrate binding site and is believed to interact with an active site lysine either by reaction or via hydrogen bonding (Figure 2) [16,17]. It is assumed that this electrophilic chlorine species is responsible for electrophilic aromatic substitution of the proximally bound substrates. Notably, an active site glutamate residue has also been found important for catalysis; however, its precise role in the reaction mechanism still remains debated [2,18].

Catalysts 2019, 9, 1030 3 of 20




Figure 2. Reaction mechanism of flavin-dependent halogenases. Reduced flavin reacts with oxygen to form a peroxyflavin species, which in turn reacts with a halide ion, generating free hypohalous acid. The hypohalous acid travels through an approximately 10 Å tunnel before reacting with an active site lysine. Through an electrophilic aromatic substitution mechanism, the halogenated aromatic compound is formed.

2. Enzyme Diversity and Substrate Scope

To date, a plethora of flavin-dependent halogenases (Fl-Hals) has been identified. Fl-Hals accept a range of different substrates but preferentially have been found to halogenate L-tryptophan (Figure 3: red square) [19], pyrrole-like compounds (Figure 3: green triangle) [20], phenolic compounds (Figure 3: blue circle) [21], and indole (Figure 3: orange square) [22]. In this section, we will give an overview of the natural diversity of flavin-dependent halogenases emphasizing the recently discovered members of this enzyme family.

The first flavin-dependent halogenases were identified in the mid-1990s [19,23]. PrnA, discovered in Pseudomonas fluorescens in 1998, is for example involved in the biosynthesis of pyrrolnitrin, a secondary metabolite derived from L-tryptophan with a strong antifungal activity [19]. PrnA catalyzes the chlorination at the 7-position of the indole moiety of L-tryptophan (Product Type I, Figure 3). Following this discovery, research intensified and many additional L-tryptophan Fl-Hals (Trp-Fl-Hals) were described [19,24–27]. The widely applied 7-tryptophan halogenase RebH, for example, stems from the bacterium Lechevalieria aerocolonigenes and its natural function is the chlorination of precursors of the antitumor agent rebeccamycin [24]. Another Fl-Hal able to halogenate at the 7-position is KtzQ found in Kutzneria sp. 744 [26]. This halogenase is involved in the biosynthesis of Kutzneride, an antifungal nonribosomal hexadepsipeptide. After chlorination at the 7-position, tryptophan is further chlorinated at the 6-position by KtzR, which has a ~120-fold preference for 7-Cl-L-Trp over L-Trp [26]. Other halogenases have a natural preference to chlorinate at the 6-position of L-Tryptophan, such as Thal from Streptomyces albogriseolus [25] and a thermophilic tryptophan halogenase (Th-Hal) found in Streptomyces violaceusniger [28]. Furthermore, SttH found in Streptomyces toxytricini [29] and the recently identified halogenases in Saccharomonospora sp. CNQ-490 (Tar14) [30], as well as a halogenase found through metagenomic screening of soil samples from the Anza-Borrego desert (BorH) [31] are able to chlorinate and brominate at the 6-position of this aromatic amino acid. The 5-position of the indole moiety of tryptophan can be modified by PyrH from Streptomyces rugosporus [27], SpmH from Streptomyces sp. SCSIO 03032 [32] and XszenFHal identified in Xenorhabdus szentirmaii [33]. Recently, a novel set of flavin-dependent halogenases called BrvH [22], xcc-b100_1333, xcc-b100_4156, and xcc-b100_4345 [34] were described. These enzymes were found to have a high sequence identity to known Trp-Fl-Hals, but could not convert L-tryptophan. This property was ascribed to the fact that certain amino acids required to stabilize tryptophan within the active site pocket were missing [22,34]. Instead, these halogenases can accept smaller substrates such as indole (Product Type III, Figure 3),

Catalysts **2019**, 9, 1030 4 of 20

which triggered us to name these enzymes "Indole Fl-Hals" in the frame of this review, and prefer bromination over chlorination. BrvH was found in *Brevundimonas* BAL3, whereas the three xcc-b100 enzymes stem from *Xanthomonas campestris* (*Xcc*). The plant pathogen *Xcc* belongs to a group of Proteobacteria that is known to infect over 350 plant species by secreting a characteristic yellow pigment called xanthomonadin, a mixture of brominated aryl polyene esters. Finally, in 2019, a viral halogenase, named VirX1, was discovered in a cyanophage and was shown to act on 6-azaindole (Product Type II, Figure 3) [35].




Figure 3. Phylogenetic tree depicting a selection of flavin-dependent halogenases and their native products. The tree was constructed using the maximum likelihood method, a bootstrap of 1000, with the alignment based on amino acids by MEGAX [36] and MUSCLE [37]. Branches corresponding to partitions reproduced in less than 50% of bootstrap replicates are collapsed.

Today, the biocatalytic toolbox contains flavin-dependent halogenases that can convert molecules beyond L-tryptophan derivatives. PrnC and PltA found in *Pseudomonas fluorescens*, for example, convert pyrrole-like substrates [19,20]. While PltA requires its substrate to be tethered to a carrier protein [20], PrnC acts on a free-standing intermediate in the biosynthesis of pyrrolnitrin. After the PrnA catalyzed chlorination of L-tryptophan to form 7-chloro-L-tryptophan (*vide infra*), which is followed by a ring rearrangement and a decarboxylation step, PrnC chlorinates the 3-position of the pyrrole ring to form aminopyrrolnitrin (Product V, Figure 3) [19]. Phenols are an additional molecule class that is known to be converted by halogenases such as Rdc2, RadH, Bmp5, and ChlA [38–41]. Phenolic halogenases typically originate from fungi except for PltM, which was isolated from *Pseudomonas fluorescens* Pf-5 [42]. Initially, PltM was identified as one of three putative halogenases encoded in the biosynthetic gene cluster of pyoluteorin (one of the others being PltA), an antifungal compound

Catalysts 2019, 9, 1030 5 of 20

containing a dichloropyrrole moiety [42]. Almost twenty years later, it was shown that PltM catalyzes mono- and di-chlorination of phloroglucinol (Product Type VI, Figure 3), yielding a compound that serves as a transcriptional factor of the pyoluteorin biosynthesis rather than a biosynthetic intermediate [43]. MalA', a rather unusual halogenase from *Malbranchea graminicola*, can act on the bulky molecule premalbrancheamide (Product Type VII, Figure 3) [44].

Except for the very electronegative fluoride ion, flavin-dependent halogenases have been shown to introduce all common halides into small molecules. However, certain anion preferences exist: The well described Trp-Fl-Hals RebH, Thal and PyrH prefer chlorination over bromination [24,25,27], while BrvH and VirX1 prefer bromination over chlorination [22,35]. For the three xcc-b100 enzymes, no chlorination was observed, and iodination was only found for Bmp5, PltM, and VirX1 [34,35,40,45] (Table 1).

Looking forward, the discovery of flavin-dependent halogenases with alternative substrate preferences will be fueled by the rapidly expanding amount of genetic information available from public databases. As gene synthesis is becoming more cost effective and high throughput assays are being established, putative halogenases can be verified quickly in an experimental setup. In a recent study from Fisher et al. [46], the authors used a genome mining approach to identify 128 putative Fl-Hals. By co-expression with the chaperones GroES and GroEL, 87 halogenase candidates were obtained in sufficient soluble amounts for the later analysis via high throughput LC-MS analysis (11 s/analysis). The soluble enzymes were screened towards electron rich substrates known to be commonly converted by Fl-Hals, as well as more complex substrates. With this approach, 39 new Fl-Hals were identified, some of which showed halogenation of complex compounds, offering advantageous starting points for further evolution [46].

Literature **Enzyme** Halogen (X) Cl > BrRebH [24] Cl > Br[25] Thal PyrH Cl > Br[27] KtzQ Cl [26] PrnA Cl [19] Th-Hal Cl, Br [47]KtzR Cl [26] Tryptophan-Fl-Hal SttH Cl, Br [29] Tar14 Cl, Br [30] SpmH Cl, Br [32] XszenFHal Cl, Br [33] **BorH** Cl, Br [31] **BrvH** Cl < Br [22] xcc-b100-4156 Br [34] Br xcc-b100-1333 [34] Indole-Fl-Hal xcc-b100-4345 Br [34] Cl < Br < I[35] VirX1 Bmp5 Br, I [40]ChlA Cl [41]PltM Cl, Br, I [45] Phenolic-Fl-Hal RadH Cl [39] Rdc2 Cl, Br [21] PrnC Cl [19] PltA Cl, Br [20] Pyrrole-Fl-Hal MalA Cl, Br [44]

Table 1. Halide versatility of Fl-Hals.

Catalysts 2019, 9, 1030 6 of 20

3. Cofactor and Reaction Engineering

As can be deduced from the reaction mechanism (Figure 2), flavin-dependent halogenases require a constant supply of reduced FADH₂ to function. In nature, the oxidized flavin species is reduced by a flavin reductase (Fre). In the case of halogenase RebH, for example, the corresponding flavin reductase called RebF was identified in the native organism *Lechevalieria aerocolonigenes* [24]. Likewise, a flavin halogenase–flavin reductase pair, PrnA and PrnF, was identified in *Pseudomonas fluorescens*. For *in vitro* studies of halogenases, however, alternative flavin reductases may be used. Examples comprise a thermophilic Fre from *Bacillus subtilis* WU-S2B [47], a Fre from *Pseudomonas fluorescens* [22], or a Fre from the *Escherichia coli* strain K12 [33]. Flavin reductases employ NADH to reduce flavin; therefore, biocatalytic applications may include an additional enzyme for the reduction of NADH such as a glucose dehydrogenase (GDH) (Figure 4) or an alcohol dehydrogenase (ADH). By adding the necessary auxiliary enzymes (Fre and GDH or ADH), halogenation biocatalysis reactions can run on the inexpensive substrate glucose or isopropanol, while the cost intensive cofactors FAD and NAD⁺ are recycled.




Figure 4. For the regeneration of FADH₂, which is needed for the production of the reactive species hypohalous acid, two auxiliary enzymes can be used: a flavin reductase (Fre) for the reduction of FAD and a glucose dehydrogenase for the reduction of NAD⁺. Overall, the co-substrate glucose is used in excess, whereas the more expensive cofactors FAD and NAD⁺ can be recycled.

Despite the described advantages, the introduction of a cofactor-recycling system renders the biocatalytic reaction more complicated, less robust, and harder to scale-up. Consequently, several studies addressing the drawbacks of cofactor regeneration have been carried out. Andorfer et al. constructed a fusion protein of a flavin halogenase and a reductase by linking the enzymes RebH and RebF. Interestingly, the fusion construct showed higher product titers in vivo for native and non-native substrates than the co-expression of the individual enzymes [48]. Furthermore, the authors suggested that the creation of the fusion protein could simplify evolution assays because the reductase must not be regularly prepared and purified. Following an alternative strategy, Frese and Sewald linked a halogenase and the auxiliary enzymes after translation by employing the bifunctional chemical glutaraldehyde. In their study, the authors overexpressed RebH (Fl-Hal), PrnF (Fre), and an alcohol dehydrogenase (use of isopropanol instead of glucose for the regeneration of NAD+) individually and subsequently crosslinked the three enzymes to so-called combi cross-linked enzymes aggregates (combiCLEAs) (Figure 5) [49]. By creating combiCLEAs, the system could be reused at least ten times and stored for several months, whereas the purified free RebH showed a considerable loss in activity after being stored for 12 weeks at 4 °C [49].

Going beyond traditional co-factor recycling schemes, Schroeder et al. showed that the need for auxiliary enzymes can be entirely overcome by using EDTA and light for the regeneration of $FADH_2$ (Figure 6). In their study, the authors reduced enzyme bound FAD with EDTA as the sacrificial electron donor and light at 450 nm. In this way, 58% of a 0.5 mM L-Trp solution was chlorinated within 25 h by

Catalysts 2019, 9, 1030 7 of 20

using the flavin halogenase PyrH. Although the light driven cofactor recycling approach had a clearly lower turnover frequency (0.72 h^{-1}) compared to the enzymatic regeneration (3.0 h^{-1}) , this study described the production of chlorinated compounds by applying only light, halide salt, air, and FADH₂ in aqueous solution [50].




Figure 5. Bromination of L-Trp using RebH cross-linked with the auxiliary enzymes PrnF and ADH (combi cross-linked enzymes aggregates (combiCLEAs)).



Figure 6. Chlorination of L-Trp by applying the flavin-dependent halogenase PyrH, EDTA, and light.

Another approach to circumvent the use of auxiliary enzymes was developed by Ismail et al. [51]. Employing a set of three tryptophan halogenases (PyrH, Thal, and RebH) in combination with an NADH mimic for FAD⁺ reduction, L-tryptophan could be selectively halogenated at the 5-, 6-, or 7-position of the indole moiety, respectively (Figure 7). Notably, the biocatalysis reactions using the NADH mimic showed a 3.5–4.7 times faster initial rate compared to the enzymatic cofactor regeneration system [51].




Figure 7. Chlorination of L-Trp using different Fl-Hals (PyrH, Thal, and RebH) applying an NADH mimic for the regeneration of FAD.

Catalysts 2019, 9, 1030 8 of 20

4. Strategies to Scale-up Biocatalytic Aromatic Halogenations

Flavin-dependent halogenases selectively install halides into small molecules under mild reaction conditions, thus providing a promising green alternative to the often toxic catalysts used in traditional organic halogenations. However, restrictions associated with the biocatalytic approach such as low expression yields and limited stability of the enzymes, as well as a narrow substrate scope currently still hinder industrial application. In order to broaden the application potential of flavin-dependent halogenases, several studies addressing the above enumerated drawbacks have been carried out in the last decade.

4.1. Protein Overexpression and Stabilization

The first attempt to upscale enzymatic halogenation was carried out by the group of Lewis [52]. In this study, the authors increased the expression level of the soluble halogenase RebH on a scale sufficient for preparative biocatalysis. Co-expression of chaperones (GroEL and GroES) in tandem with cell culture condition optimization led to a 10-fold increase of enzyme concentration in *E. coli* (111 mg L⁻¹) compared to previously reported values [24]. In the same study, a regeneration system utilizing glucose dehydrogenase (GDH) together with a fusion protein of reductase RebF and maltose binding protein (MBP) for preparative scale reactions (10 mg) was developed. High halogenation yields were observed for the transformation of several non-natural bioactive substrates including indoles and naphthalenes highlighting the synthetic utility of the enzyme (Figure 8). In order to explore the accessible synthesis scale, 100 mg of L-tryptophan were used as a substrate for chlorination by crude cell lysate of RebH. Although the substrate was not fully converted, the enzyme remained active under these conditions, and a 69% final yield could be obtained [52].




Figure 8. Product structure and isolated yields of preparative scale RebH catalyzed halogenation. HPLC conversion yields are shown in brackets.

The preparative efficiency of RebH has also been explored by Frese and Sewald who developed a multifunctional biocatalytic system exploiting the technique of cross-linked enzyme aggregates (combiCLEAs, *vide infra*). Using this enzymatic preparation, complete bromination of L-tryptophan was achieved after eight days, and 1.813 g of L-7-bromotryptophan TFA were isolated in high purity (isolated yield 92%). CombiCLEA formation was found to increase significantly the long-term stability of RebH, thus facilitating the enzymatic regioselective halogenation for gram scale synthesis [49]. In the same manner, the Micklefield group halogenated non-natural substrates such as anthranilamide and tryptophol using CLEAs of four different Fl-Hals as the first step of a chemoenzymatic reaction [5].

The instability of flavin-dependent halogenases in certain reaction conditions has also been addressed by directed evolution. The Lewis group was among the first to generate a thermostable halogenase variant by employing three rounds of error prone PCR and recombinations. The obtained RebH variant, which contained eight mutations, was characterized by an 18 °C increased melting

Catalysts 2019, 9, 1030 9 of 20

temperature compared to the wildtype enzyme. However, the catalytic efficiency of the mutant was significantly decreased at 21 °C owing to a lower conformational flexibility of the enzyme [53]. Exploiting a high throughput assay for rapid library screening, Schnepel et al. also evolved thermostable flavin-dependent halogenases. In their study, a doubly mutated variant was found with a 10 °C increase of its T_m compared to the wildtype enzyme. Unlike the wildtype enzyme, which significantly lost its activity after 2–3 h of incubation at 40 °C, the new variant, named Thal-GR, remained active even after 6 h of incubation at this temperature. In addition to the increased catalyst stability, the specific activity of the mutant Thal-GR was also 2.5 times higher than that of the wildtype [54]. Based on these results, the same group published a comprehensive study to further improve the thermostability of the generated variant Thal-GR three years later. Combining different mutagenesis strategies, the authors identified seven variants with higher thermostability compared to the native enzyme. A variant called Thal-GLV exhibited a good stability-activity relationship as it showed a significant increase in thermostability ($\Delta T_{50} = 16$ °C, $\Delta T_{m} = 23.5$ °C) compared to the wildtype, while exhibiting a 2.4-fold increase in activity at 25 °C. The stabilizing effect of the mutations has been linked to an increased association of the halogenase monomers to form homodimers in solution. Moreover, a crucial site with a strong effect on substrate selectivity was also identified. The single mutant Thal-S359G showed a distinct preference towards L-tryptophan, and only 17% bromination of D-tryptophan was observed compared to >99% in the case of the wildtype enzyme [55]. In a complementary approach to identify thermostable halogenases, the Micklefield group identified a thermophilic tryptophan halogenase (Th-Hal) from a thermophilic and halotolerant strain of *Streptomyc*es via computational genome mining. The newly discovered thermostable flavin halogenase was characterized by an approximately 10 °C higher melting temperature (T_m = 47.8 °C) than other known Fl-Hals such as RebH, SttH, PrnA, KtzR, and PyrH. Combining this thermostable enzyme with a thermophilic flavin reductase (Th-Fre) from Bacillus subtilis WU-S2, the authors established a more efficient and robust biocatalytic system that led to 74% conversion of a 0.5 mM solution of tryptophan at 45 °C in contrast to other known halogenases, which gave significantly lower conversions (around 40% for PyrH) using the same reaction conditions [47].

4.2. Substrate Scope and Regioselectivity

To assess the substrate scope of flavin-dependent halogenases, Frese et al. showed that RebH can halogenate substrates beyond the native L-tryptophan such as C-5- and C-6-substituted fluoro-, amino-, chloro-, hydroxy-, and methyl-tryptophans [56]. Subsequently, Shepherd et al. successfully submitted the non-indolic substrates kynurenine, anthranilamide, anthranilic acid, and other anilines to the regiocomplementary tryptophan halogenases PyrH and PrnA highlighting that also these enzymes possess substrate promiscuity, which can be exploited in applications (Figure 9) [57].




Figure 9. Non-indolic substrates accepted for chlorination. X: PyrH halogenation site, Y: PrnA halogenation site.

Catalysts 2019, 9, 1030 10 of 20

The Tsodikov group investigated the accepted substrate spectrum of the halide versatile phenolic halogenase PltM. The authors found that PltM can halogenate several small phenolic and aniline derivatives. Encouraged by these findings, the study was successfully continued towards more bulky compounds including FDA approved drugs and natural products such as terbutaline, fenoterol, resveratrol, and catechin (Figure 10) [45]. Notably, no halogenation activity was observed in the case of a nitrobenzene derivative due to the strongly electron withdrawing nitro group that prevented the halogenation of the substrate.

Figure 10. FDA approved drugs (terbutaline, fenoterol) and natural products (resveratrol, catechin) accepted by the phenolic halogenase PltM [45].

Tailoring the substrate scope of enzymes towards desired molecules has also been approached through protein engineering. Interestingly, even enzymes exhibiting very little initial substrate promiscuity could be altered in this way. Following a substrate walking approach, Payne et al., for example, extended the substrate scope of the natural tryptophan halogenase RebH towards the significantly larger biologically active compounds yohimbine and carvedilol (Figure 11). Starting with a thermostable mutant of RebH (1-PVM), the authors performed three rounds of random mutagenesis and screening and could generate variants that selectively halogenate a number of unnatural substrates with a range of sizes, substitutions, and biological activities. Although the majority of the beneficial mutations were found close to the active site, a crucial mutation (A442V) was located distal to the active center. This finding highlights the worth of random mutagenesis in directed evolution strategies as this technique may identify amino acid positions that are difficult to predict via rational design strategies [58].




Figure 11. RebH catalyzed halogenation of various substrates indicating the isolated product yields and conversion yields (in brackets). ^a Multiple closely eluting products were observed and were not individually isolated.

Catalysts 2019, 9, 1030 11 of 20

Enzyme engineering has also been employed to alter the regioselectivity of halogenases in order to control the site of halogenation in small molecules. In a first example of this approach, the structure of PrnA, a tryptophan 7-halogenase, was analyzed, and three aromatic residues around the enzyme's active site were mutated to alanine. One identified variant, F103A, was found to halogenate both at the C7 and C5 position of the tryptophan indole ring exhibiting a 2:1 ratio of the products. The exchange of the large amino acid phenylalanine with the smaller alanine allowed the substrate to adopt its "native" orientation but also bind in a similar mode as in the tryptophan 5-halogenase PyrH [59]. In a similar manner, structure guided mutagenesis was employed by Shepherd et al. in 2016 to alter the regioselectivity of tryptophan 6-halogenase SttH. The generated triple mutant SttH L460F/P461E/P462T transformed 75% of the supplied tryptophan into the C5-halogenated product, whereas the wildtype enzyme exhibited almost the same activity towards the C6-halogenated product [60]. In the same year, Lewis and co-workers published a thorough study in which RebH was engineered for altered regioselectivity. High throughput MALDI-MS analysis was used to screen the transformation of deuterium substituted probe substrates. Utilizing a previously evolved variant, which was able to chlorinate tryptamine with 99% selectivity towards the C7 position, the authors identified two variants, named 8F and 10S, which could selectively chlorinate tryptamine at the C6 and C5 site, respectively. Additional reverse mutations (mutations that lead to the initial starting sequence) proved beneficial for the enzymes activity while maintaining the achieved selectivity [61]. In a structure-based protein engineering approach, Moritzer et al. substituted five residues in the substrate binding site of Thal by the corresponding amino acids of the closely related tryptophan halogenase RebH to switch regioselectivity from the 6- to 7-position. The resulting variant, named Thal-RebH5, exhibited a 95% change in regioselectivity towards C7-halogenation for both chlorination and bromination of L-tryptophan, further confirming the importance of the binding pose of the substrate for the regioselectivity outcome [62]. Building on previous learnings, Payne et al. recently reported the first enantioselective desymmetrization of methylenedianinelines catalyzed by engineered RebH variants. Docking simulations and structure guided mutagenesis afforded mutants with improved activity and altered selectivity [63].

4.3. Biosynthetic Pathways

Fueled by the discovery of novel halogenases with interesting properties, the incorporation of halogenases into biosynthetic pathways has become an attractive tool to increase the diversity of accessible products and to synthesize bioactive molecules or valuable intermediates.

In 2010, Roy et al. carried out the first introduction of a halogenase gene into a synthetically unrelated pathway. In their study, the authors complemented the biosynthesis of the uridyl peptide antibiotic (UPA) pacidamycin from Streptomyces coeruleorubidus with the prnA gene expressing the tryptophan 7-halogenase PrnA. The resulting strain could produce the "unnatural" chloropacidamycin in a yield of 1 mg per liter culture with a ratio to its non-chlorinated analogue as high as 4:1. The installed chlorine then served as a handle, enabling the selective chemical functionalization of the antibiotic to yield a variety of derivatives [64]. Today, halogenase genes have also been integrated into medicinal plant metabolisms in order to produce chlorinated indole alkaloids with altered and/or improved pharmacological properties. Two prokaryotic halogenase genes encoding 7-tryptophan halogenase RebH or 5-tryptophan halogenase PyrH together with RebF as the partner reductase were introduced into Catharanthus roseus. It was reported that both halogenases function productively in the plant cell environment leading to the formation of the corresponding halotryptophans (7- or 5-halotryptophan), which subsequently enter the metabolic pathway of the plant cells to form chlorinated indole alkaloids. However, the efficiency of tryptophan decarboxylase, an enzyme that converts tryptophan to tryptamine, was significantly lower towards the halogenated substrates. This led to an accumulation of substantial levels of a non-natural intermediate, which had an adverse effect on the morphology and the growth rate of tissues [65]. To overcome this negative outcome, Glenn et al. employed site directed mutagenesis to generate a RebH mutant, which preferentially halogenates tryptamine rather than the native substrate

Catalysts 2019, 9, 1030 12 of 20

tryptophan. Using this approach, the accumulation of 7-chlorotryptophan and its negative effect on the cell metabolism could be bypassed [66].

The potential application of plants as platforms for the manufacture of rare and valuable halogenated products has been also studied by Fräbel et al. Tryptophan 6-halogenase from *Streptomyces toxytricini* SttH has been successfully integrated into tobacco plants allowing the formation of chlorotryptophan in the cytosol when co-expressed with the flavin reductase RebF. The introduction of an additional flavin-dependent halogenase (RebH) into the metabolic setup of the plant led to the formation of 6,7-dichlorotryptophan, while a novel precursor of monoterpenoid indole alkaloids, 6-chlorotryptamine, was observed when SttH was co-expressed with tryptophan decarboxylase (TDC). Notably, SttH and RebH remained active even in the absence of the partner reductase when localized in chloroplasts, indicating the presence of sufficient reduction equivalents in these organelles for halogenation reactions [67].

Following a combinatorial biosynthesis approach, Wang et al. combined enzymes from different sources in *Escherichia coli* to generate valuable compounds. Using a multiple vector system, the fungal Fl-Hal Rdc2 was co-expressed with tyrosine ammonia-lyase (TAL), 4-coumarate:CoA ligase (4CL), and stilbene synthase (STS), resulting in a novel chlorinated derivative in addition to resveratrol. This novel compound was identified as 2-chloro-resveratrol highlighting the broad substrate scope of Rdc2 [68].

4.4. Chemoenzymatic Synthesis

Chemoenzymatic synthesis has proven to be a powerful tool for the manufacture of complex compounds offering numerous advantages such as higher yields, decreased costs, environmental benefits, and high selectivity compared to purely chemical strategies [69]. In this context, the site-specific enzymatic halogenation of natural products can provide halogenated compounds that are of interest for the further functionalization by cross-coupling chemistry. The combination of chemo- and enzyme catalysis can thus lead to the formation of C-C, C-N, C-F, and C-O bonds from C-H positions, which were beyond the scope of chemocatalytic activation chemistry.

Chemical modification through Pd catalyzed cross-coupling of a biosynthetically halogenated natural product has been reported by the group of Goss. Employing mild reaction conditions to account for the thermal instability of the substrate chloropacidamycin, the authors obtained various 7-aryl-pacidamycin derivatives in high yields. This functionalization approach could not only be applied on purified natural compounds, but also worked when using crude extracts of the halogenated substrates [64].

In a similar manner, Pd catalyzed Suzuki–Miyaura cross-coupling (SMC) reactions have been adopted by the O'Connor group to synthesize aryl and heteroaryl analogues of monoterpene indole alkaloids. Exploiting the technique of mutasynthesis in *C. roseus* hairy root cultures, the authors introduced a chemical halogen handle into the indole moiety of the monoterpene indole alkaloids followed by the subsequent chemical derivatization using the crude cell extracts. Based on their promising results, the authors further scaled up the cross-coupling reactions using 16 g of the crude hairy root extract to obtain milligram quantities of three alkaloid analogs [70]. Durak et al. further expanded the application scope of the chemoenzymatic strategy by derivatizing non-native bioactive small aromatic molecules such as carvedilol, pindolol, thenalidine, and tryptoline and its derivatives. Two RebH variants, 3-SS and 4-V, were used for the selective halogenation of the aforementioned compounds followed by subsequent Pd catalyzed cross-coupling reactions with boronic acids, amines, and trifluoroethanol on the crude biocatalysis extracts to generate new C-C, C-N, and C-O bonds [71].

Although the advantages of chemoenzymatic reactions for the synthesis of demanding and complex compounds has been successfully demonstrated, the detrimental effects of protein contaminants on the metal catalyst require an intermediate extraction step of the halogenated precursor that limits process scale-up. To address this challenge, the group of Sewald utilized combiCLEAs of several Fl-Hals in a single pot approach [72]. In this study, a bromine substituent was introduced biocatalytically at the C5,

Catalysts 2019, 9, 1030 13 of 20

C6, or C7 position of L-tryptophan on a preparative scale. After filtration of the biocatalyst, a SMC reaction led to an efficient modification of the halogenated compounds, and the resulting cross-coupling product could subsequently be Boc protected and purified for further applications. This three-step one pot approach is an important proof-of-concept for the development of more sustainable and consecutive biohalogenation-chemocatalytic cross-coupling processes.

Latham et al. further simplified the one pot halogenase-SMC cascade by separating the protein from the Pd catalyst using polydimethylsiloxane membranes (PDMS). Compartmentalization was achieved thanks to the hydrophobic nature of the PDMS membranes, which allowed for the diffusion of non-polar compounds such as substrates and intermediates while the diffusion of polar compounds (enzymes, Pd catalysts, and cofactors) was prevented (Figure 12). Combining this method with halogenase CLEAs led to higher concentrations of the aryl halide and reduced Pd loading (2 mol%) compared to free pure protein reactions (Pd loading: 10 mol%) [5].




Figure 12. Polydimethylsiloxane (PDMS) compartmentalization. PDMS membrane permits diffusion of non-polar compounds (substrates, intermediates), while polar compounds such as enzymes, Pd catalysts, and cofactors are blocked. This compartmentalization overcomes the incompatibility of the enzyme and transition metal that reduces the efficiency of the chemoenzymatic process. Figure adapted from [5].

Further pioneering the one pot chemoenzymatic reactions, the Goss group combined synthetic biology with synthetic chemistry. After an optimization of the cultivation media of the engineered strains to minimize the impact of media components on the cross-coupling efficiency, the authors developed a biological system for the generation of brominated metabolites that can synchronously be modified through cross-coupling in living cultures (Figure 13). This approach provides the advantage of a simplified product isolation and a continuously producing biosynthetic system [6].

Catalysts 2019, 9, 1030 14 of 20




Figure 13. In culture biosynthesis and cross-coupling of Br-pacidamycin-D. The engineered strain of *S. coelicolor* RG-1104 grown in the presence of sodium bromide is able to produce Br-pacidamycin-D. The brominated compound is subsequently modified through Pd catalyzed Suzuki–Miyaura cross-coupling reactions under mild conditions.

5. Conclusions

The selective halogenation of small molecules is of high interest for many industries and is especially sought after in the pharmaceutical industry and agrochemistry [2,3]. Today, biocatalytic halogenations are promising tools for the preparation of small quantities of selectively derivatized products (Table 2), which can be used in medicinal chemistry, or serve as intermediates for the total synthesis of complex molecules (Chapter 4.4). However, to our knowledge, more than a gram quantity of halogenated target compound has not yet been prepared (Table 2), illustrating two of the current challenges in aromatic halogenase catalysis: the enzymes suffer from low productivity and limited scalability. Thus, in order to expand the application scope of flavin-dependent halogenases, further studies aimed to broaden the substrate scope and increase the robustness of these enzymes are required. These can entail bioinformatic studies to identify additional members of the flavin-dependent halogenase superfamily with an extended substrate scope [46] or higher thermostability [47]. Additionally, approaches such as the "catalophore" strategy might be successful in the identification of novel flavin-dependent halogenases [73]. In this bioinformatic method, Steinkellner et al. carried out a structure guided search for the discovery of ene-reductases by predicting enzyme activity based on three-dimensional constellations of functional groups.

Table 2. Examples of preparative scale applications of flavin-dependent halogenases.

Enzyme	Scale (mg)	Substrate	Halogen Insertion	Conversion Yield %/ Isolated Product Yield %	Ref.
PyrH (combiCLEAs)	136	Anthranilamide		n.d. ^[a]	[5]
PyrH and SttH (combiCLEAs)	15	3-Indolepropionic acid	Br		
RebH (combiCLEAs)	24	Tryptophol			
	16	L-tryptophan		-/62.5	[47]
	18	1-methyl-L-tryptophan	Cl	-/12	
Th-Hal (purified)	17	5-hydroxy-L-tryptophan		-/16	
m-riai (purilieu)	16	L-kynurenine,		-/21	
	11	Anthranilic acid		-/8	
	11	Anthranilamide		-/19	

Catalysts **2019**, 9, 1030

Table 2. Cont.

Enzyme	Scale (mg)	Substrate	Halogen Insertion	Conversion Yield %/ Isolated Product Yield %	Ref.
RebH (combiCLEAs)	1000	L-tryptophan		100/-	
	40	D-tryptophan	Br	57 /	[49]
	40	L-5-hydroxytryptophan		53 /	
RebH (purified)	10	L-tryptophan	Cl	94/74	
ч ,	10	D-tryptophan	Br	97/85	
RebH (purified)				99/78	
icori (puincu)		Tryptamine		98/53	
		N - Ω -methyltryptamine		65/65	
		Tryptophol		95/95	
			C1	•	
		2-methyltryptamine	CI	96/60	[52]
		5-methyltryptamine		99/58	
		2,3-disubstituted indole tryptoline		58/54	
		Indole		64/53	
		2-aminonaphthalene		98/93	
		1-naphthol		95/59	
RebH (lysate)	100	L-tryptophan	Cl	74/69	
		L-tryptophan	Cl	-/69	[53]
		2-methyltryptamine		-/56	
RebH (purified)	10	2-aminonaphthalene		-/62	
		Tryptoline		-/67	
D. 11		пурюше		707	
PyrH (combiCLEAs)	50	L-tryptophan		-/76	
(COMDICEEAS)					
Thal			-	150	[54]
(combiCLEAs)	50	L-tryptophan	Br	-/61	[]
·					
RebH	150	L-tryptophan		-/84	
(combiCLEAs)		,F.o.F			
SttH (combiCLEAs)	100	Anthranilamide	Cl	-/25	[60]
RebH variants 0S/8F/10S (purified)	10	Tryptamine	C1	98/73/78 ^[b]	[61]
(parmea)			Cl	30/-	
Thal-RebH5 variant (lysate)	30	L-tryptophan	Br	15/-	[62]
PohH variant 4 V (nurified)	10	t-Bu dianiline methane	Cl	80/-	[63]
RebH variant 4-V (purified)	10		CI	· · · · · · · · · · · · · · · · · · ·	[63]
		Tryptoline		-/78	
RebH variant 3-SS		Eleagnine		-/83	
(purified)	10	Pinoline	Cl	-/80	
		Tetrahydroharmine		-/79	
		Debromo defermentalement		160	[58]
		Debromodeformylflustrabromine		-/68 /5.4	. ,
RebH variant 4-V		Yohimbine		-/54	
(purified)	10	Pindolol	Cl	-/93	
		Carazolol		-/79	
		Carvedilol		-/69	
RebH variant 3-SS (purified)	10	Tryptoline	Br		
RebH variant 4-V (purified)	10	Carvedilol	Cl		_
	-0	Pindolol	Br	n.d. ^[a]	[71]
		Thenalidine	DI		
RebH/ThaI/PyrH					
	150	L-tryptophan	Br	100 ^[c]	[72]

[[]a] Enzymatic halogenation yields not determined for these chemoenzymatic cascade reactions. [b] Isolated yields % for the three different variants studied (0S/8F/10S). [c] Conversion yield % was 100 for all cases of immobilized Fl-Hals studied.

Catalysts 2019, 9, 1030 16 of 20

Following the discovery of promising wildtype enzymes, engineering strategies that should equally consider enzyme stability and activity will, at least to some extent, inform about the structure-function relationship in flavin-dependent halogenases. In this respect, in silico design based on energy functions might be a very valuable tool, as methods such as Rosetta_ddg and FireProt have been proven to optimize protein structures successfully [74–78]. The obtained knowledge may then lead to the development of tailored enzyme variants, which through their increased stability, activity and, robustness may facilitate industrial usage. Looking forward, engineering flavin-dependent halogenases towards the acceptance of more electron poor substrates [79] through increasing the electrophilicity of the halogenating species will be a way to further enhance their applicability. As proposed by Latham et al., reaction engineering aspects, such as optimizing oxygen concentration in the reaction medium and the management of the level of reactive oxygen species could be further levers to increase flavin-dependent halogenase productivity [2].

Author Contributions: Conceptualization: J.B., A.P., and R.B; writing: J.B, A.P and R.B.

Funding: This research was funded by the Swiss State Secretariat for Education, Research and Innovation (Federal project contribution 2017–2020, P-14: Innovation in Biocatalysis).

Acknowledgments: We gratefully acknowledge financial support by the Swiss State Secretariat for Education, Research and Innovation (Federal project contribution 2017–2020, P-14: Innovation in Biocatalysis).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.

References

- Gribble, G.W. A recent survey of naturally occurring organohalogen compounds. Environ. Chem. 2015, 12, 396–405. [CrossRef]
- 2. Latham, J.; Brandenburger, E.; Shepherd, S.A.; Menon, B.R.K.; Micklefield, J. Development of Halogenase Enzymes for Use in Synthesis. *Chem. Rev.* **2018**, *118*, 232–269. [CrossRef] [PubMed]
- 3. Herrera-Rodriguez, L.; Khan, F.; Robins, K.; Meyer, H.-P. Perspectives on biotechnological halogenation. *Chim. Oggi Chem. Today* **2011**, *29*, 31–33.
- 4. Njardarson, J.T. Top 200 Small Molecule Pharmaceuticals by Retail Sales in 2018. Available online: https://njardarson.lab.arizona.edu/content/top-pharmaceuticals-poster (accessed on 4 November 2019).
- 5. Latham, J.; Henry, J.M.; Sharif, H.H.; Menon, B.R.K.; Shepherd, S.A.; Greaney, M.F.; Micklefield, J. Integrated catalysis opens new arylation pathways via regiodivergent enzymatic C-H activation. *Nat. Commun.* **2016**, 7. [CrossRef] [PubMed]
- 6. Sharma, S.V.; Tong, X.; Pubill-Ulldemolins, C.; Cartmell, C.; Bogosyan, E.J.A.; Rackham, E.J.; Marelli, E.; Hamed, R.B.; Goss, R.J.M. Living GenoChemetics by hyphenating synthetic biology and synthetic chemistry in vivo. *Nat. Commun.* **2017**, *8*, 1–9. [CrossRef] [PubMed]
- 7. Prakash, G.K.S.; Mathew, T.; Hoole, D.; Esteves, P.M.; Wang, Q.; Rasul, G.; Olah, G.A. *N*-halosuccinimide/BF₃-H₂O, efficient electrophilic halogenating systems for aromatics. *J. Am. Chem. Soc.* **2004**, 126, 15770–15776. [CrossRef] [PubMed]
- 8. Alonso, F.; Beletskaya, I.P.; Yus, M. Metal-mediated reductive hydrodehalogenation of organic halides. *Chem. Rev.* **2002**, *102*, 4009–4091. [CrossRef]
- 9. Chung, W.J.; Vanderwal, C.D. Stereoselective Halogenation in Natural Product Synthesis. *Angew. Chem. Int. Ed.* **2016**, *55*, 4396–4434. [CrossRef]
- 10. Timmins, A.; De Visser, S.P. A comparative review on the catalytic mechanism of nonheme iron hydroxylases and halogenases. *Catalysts* **2018**, *8*, 1–25. [CrossRef]
- 11. Yeh, E.; Cole, L.J.; Barr, E.W.; Bollinger, J.M.; Ballou, D.P.; Walsh, C.T. Flavin redox chemistry precedes substrate chlorination during the reaction of the flavin-dependent halogenase RebH. *Biochemistry* **2006**, 45, 7904–7912. [CrossRef]
- 12. Dong, C. Tryptophan 7-Halogenase (PrnA) Structure Suggests a Mechanism for Regioselective Chlorination. *Science* **2005**, *309*, 2216–2219. [CrossRef] [PubMed]

Catalysts 2019, 9, 1030 17 of 20

13. Zhu, X.; De Laurentis, W.; Leang, K.; Herrmann, J.; Ihlefeld, K.; van Pée, K.H.; Naismith, J.H. Structural Insights into Regioselectivity in the Enzymatic Chlorination of Tryptophan. *J. Mol. Biol.* **2009**, 391, 74–85. [CrossRef] [PubMed]

- 14. Dong, C.; Kotzsch, A.; Dorward, M.; Van Pée, K.H.; Naismith, J.H. Crystallization and X-ray diffraction of a halogenating enzyme, tryptophan 7-halogenase, from *Pseudomonas fluorescens*. *Acta Cryst.* **2004**, 60, 1438–1440.
- 15. Bitto, E.; Huang, Y.; Bingman, C.A.; Singh, S.; Thorson, J.S.; Phillips, G.N., Jr. The structure of flavin-dependent tryptophan 7-halogenase RebH. *Proteins* **2007**, *70*, 289–293. [CrossRef] [PubMed]
- 16. Yeh, E.; Blasiak, L.C.; Koglin, A.; Drennan, C.L.; Walsh, C.T. Chlorination by a long-lived intermediate in the mechanism of flavin-dependent halogenases. *Biochemistry* **2007**, *46*, 1284–1292. [CrossRef] [PubMed]
- 17. Flecks, S.; Patallo, E.P.; Zhu, X.; Ernyei, A.J.; Seifert, G.; Schneider, A.; Dong, C.; Naismith, J.H.; Van Pée, K.H. New insights into the mechanism of enzymatic chlorination of tryptophan. *Angew. Chem. Int. Ed.* **2008**, 47, 9533–9536. [CrossRef]
- 18. Andorfer, M.C.; Lewis, J.C. Understanding and Improving the Activity of Flavin-Dependent Halogenases via Random and Targeted Mutagenesis. *Annu. Rev. Biochem.* **2018**, *87*, 159–185. [CrossRef]
- 19. Altmann, A.; Fischer, I.; Weislo, L.J.; Lanahan, M.; Ligon, J.M. Functions Encoded by Pyrrolnitrin Biosynthetic Genes from *Pseudomonas fluorescens*. *J. Bacteriol.* **1998**, *180*, 1939–1943.
- 20. Dorrestein, P.C.; Yeh, E.; Garneau-Tsodikova, S.; Kelleher, N.L.; Walsh, C.T. Dichlorination of a pyrrolyl-S-carrier protein by FADH2-dependent halogenase PltA during pyoluteorin biosynthesis. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 13843–13848. [CrossRef]
- 21. Zeng, J.; Zhan, J. A Novel Fungal Flavin-Dependent Halogenase for Natural Product Biosynthesis. *ChemBioChem* **2010**, *11*, 2119–2123. [CrossRef]
- 22. Neubauer, P.R.; Widmann, C.; Wibberg, D.; Schröder, L.; Frese, M.; Kottke, T.; Kalinowski, J.; Niemann, H.H.; Sewald, N. A flavin-dependent halogenase from metagenomic analysis prefers bromination over chlorination. *PLoS ONE* **2018**, *13*, 1–21. [CrossRef] [PubMed]
- 23. Dairi, T.; Nakano, T.; Aisaka, K.; Katsumata, R.; Hasegawa, M. Cloning and Nucleotide Sequence of the Gene Responsible for Chlorination of Tetracycline. *Biosci. Biotech. Biochem.* **1995**, *59*, 1099–1106. [CrossRef] [PubMed]
- 24. Yeh, E.; Garneau, S.; Walsh, C.T. Robust in vitro activity of RebF and RebH, a two-component reductase/halogenase, generating 7-chlorotryptophan during rebeccamycin biosynthesis. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3960–3965. [CrossRef] [PubMed]
- 25. Seibold, C.; Schnerr, H.; Rumpf, J.; Kunzendorf, A.; Hatscher, C.; Wage, T.; Ernyei, A.J.; Dong, C.; Naismith, J.H.; van Pée, K.H. A flavin-dependent tryptophan 6-halogenase and its use in modification of pyrrolnitrin biosynthesis. *Biocatal. Biotransformation* **2006**, *24*, 401–408. [CrossRef]
- Heemstra, J.R.; Walsh, C.T. Tandem action of the O₂-and FADH₂-dependent halogenases KtzQ and KtzR produce 6,7-dichlorotryptophan for kutzneride assembly. J. Am. Chem. Soc. 2008, 130, 14024–14025. [CrossRef]
- 27. Zehner, S.; Kotzsch, A.; Bister, B.; Süssmuth, R.D.; Méndez, C.; Salas, J.A.; Van Pée, K.H. A regioselective tryptophan 5-halogenase is involved in pyrroindomycin biosynthesis in *Streptomyces rugosporus* LL-42D005. *Chem. Biol.* 2005, 12, 445–452. [CrossRef]
- 28. Bennett, M.R.; Thompson, M.L.; Shepherd, S.A.; Dunstan, M.S.; Herbert, A.J.; Smith, D.R.M.; Cronin, V.A.; Menon, B.R.K.; Levy, C.; Micklefield, J. Structure and Biocatalytic Scope of Coclaurine *N*-Methyltransferase. *Angew. Chem. Int. Ed.* **2018**, *57*, 10600–10604. [CrossRef]
- 29. Zeng, J.; Zhan, J. Characterization of a tryptophan 6-halogenase from *Streptomyces toxytricini*. *Biotechnol*. *Lett.* **2011**, 33, 1607–1613. [CrossRef]
- 30. Luhavaya, H.; Sigrist, R.; Chekan, J.R.; McKinnie, S.M.K.; Moore, B.S. Biosynthesis of L-4-Chlorokynurenine, an Antidepressant Prodrug and a Non-Proteinogenic Amino Acid Found in Lipopeptide Antibiotics. *Angew. Chem. Int. Ed.* **2019**, *58*, 8394–8399. [CrossRef]
- 31. Lingkon, K.; Bellizi, J. Structure and activity of the thermophilic tryptophan-6 halogenase. *ChemBioChem* **2019**. [CrossRef]
- 32. Liu, Z.; Ma, L.; Zhang, L.; Zhang, W.; Zhu, Y.; Chen, Y.; Zhang, W.; Zhang, C. Functional characterization of the halogenase SpmH and discovery of new deschloro-tryptophan dimers. *Org. Biomol. Chem.* **2019**, 17, 1053–1057. [CrossRef] [PubMed]

Catalysts 2019, 9, 1030 18 of 20

33. Domergue, J.; Erdmann, D.; Jouenne, A.F.; Petit, J.L.; Debard, A.; de Berardinis, V.; Vaxelaire, C.V.; Zaparucha, A. Xszen FHal, a novel tryptophan 5—halogenase from *Xenorhabdus szentirmaii*. *AMB Express* **2019**, *9*, 1–11. [CrossRef] [PubMed]

- 34. Ismail, M.; Frese, M.; Patschkowski, T.; Ortseifen, V.; Niehaus, K.; Sewald, N. Flavin-Dependent Halogenases from *Xanthomonas campestris* pv. *campestris* B100 Prefer Bromination over Chlorination. *Adv. Synth. Catal.* **2019**, *361*, 2475–2486. [CrossRef]
- 35. Gkotsi, D.S.; Ludewig, H.; Sharma, S.V.; Connolly, J.A.; Dhaliwal, J.; Wang, Y.; Unsworth, W.P.; Taylor, R.J.K.; Mclachlan, M.M.W.; Shanahan, S.; et al. A marine viral halogenase that iodinates diverse substrates. *Nat. Chem.* **2019**. [CrossRef] [PubMed]
- 36. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. *Mol. Biol. Evol.* **2018**, *35*, 1547–1549. [CrossRef]
- 37. Edgar, R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* **2004**, *32*, 1792–1797. [CrossRef]
- 38. Reeves, C.D.; Hu, Z.; Reid, R.; Kealey, J.T. Genes for the biosynthesis of the fungal polyketides hypothemycin from *Hypomyces subiculosus* and radicicol from *Pochonia chlamydosporia*. *Appl. Environ. Microbiol.* **2008**, 74, 5121–5129. [CrossRef]
- 39. Wang, S.; Xu, Y.; Maine, E.A.; Wijeratne, E.M.K.; Espinosa-Artiles, P.; Gunatilaka, A.A.L.; Molnár, I. Functional Characterization of the Biosynthesis of Radicicol, an Hsp90 Inhibitor Resorcylic Acid Lactone from *Chaetomium chiversii*. *Chem. Biol.* **2008**, *15*, 1328–1338. [CrossRef]
- Agarwal, V.; El Gamal, A.A.; Yamanaka, K.; Poth, D.; Kersten, R.D.; Schorn, M.; Allen, E.E.; Moore, B.S. Biosynthesis of polybrominated aromatic organic compounds by marine bacteria. *Nat. Chem. Biol.* 2014, 10, 640–647. [CrossRef]
- 41. Neumann, C.S.; Walsh, C.T.; Kay, R.R. A flavin-dependent halogenase catalyzes the chlorination step in the biosynthesis of *Dictyostelium differentiation*-inducing factor 1. *Proc. Natl. Acad. Sci. USA* **2010**, 107, 5798–5803. [CrossRef]
- 42. Nowak-Thompson, B.; Chaney, N.; Wing, J.S.; Gould, S.J.; Loper, J.E. Characterization of the pyoluteorin biosynthetic gene cluster of *Pseudomonas fluorescens* Pf-5. *J. Bacteriol.* **1999**, *181*, 2166–2174. [PubMed]
- 43. Yan, Q.; Philmus, B.; Chang, J.H.; Loper, J.E. Novel mechanism of metabolic co-regulation coordinates the biosynthesis of secondary metabolites in *Pseudomonas protegens*. *Elife* **2017**, *6*, 1–24. [CrossRef] [PubMed]
- 44. Fraley, A.E.; Garcia-Borra, M.; Tripathi, A.; Khare, D.; Mercado-Marin, E.V.; Tran, H.; Dan, Q.; Webb, G.P.; Watts, K.R.; Crews, P.; et al. Function and Structure of MalA/MalA', Iterative Halogenases for Late-Stage C-H Functionalization of Indole Alkaloids. *J. Am. Chem. Soc.* 2017, 139, 12060–12068. [CrossRef] [PubMed]
- 45. Mori, S.; Pang, A.H.; Chandrika, N.T.; Garneau-Tsodikova, S.; Tsodikov, O.V. Unusual substrate and halide versatility of phenolic halogenase PltM. *Nat. Commun.* **2019**, *10*, 1–11. [CrossRef] [PubMed]
- Fisher, B.F.; Snodgrass, H.M.; Jones, K.A.; Andorfer, M.C.; Lewis, J.C. Site-Selective C-H Halogenation using Flavin-Dependent Halogenases Identified via Family-Wide Activity Profiling. *ChemRxiv* 2019, 5, 1844–1856. [CrossRef]
- 47. Menon, B.R.K.; Latham, J.; Dunstan, M.S.; Brandenburger, E.; Klemstein, U.; Leys, D.; Karthikeyan, C.; Greaney, M.F.; Shepherd, S.A.; Micklefield, J. Structure and biocatalytic scope of thermophilic flavin-dependent halogenase and flavin reductase enzymes. *Org. Biomol. Chem.* **2016**, *14*, 9354–9361. [CrossRef]
- 48. Andorfer, M.C.; Belsare, K.D.; Girlich, A.M.; Lewis, J.C. Aromatic Halogenation by Using Bifunctional Flavin Reductase–Halogenase Fusion Enzymes. *ChemBioChem* **2017**, *18*, 2099–2103. [CrossRef]
- 49. Frese, M.; Sewald, N. Enzymatic halogenation of tryptophan on a gram scale. *Angew. Chem. Int. Ed.* **2015**, 54, 298–301. [CrossRef]
- 50. Schroeder, L.; Frese, M.; Müller, C.; Sewald, N.; Kottke, T. Photochemically Driven Biocatalysis of Halogenases for the Green Production of Chlorinated Compounds. *ChemCatChem* **2018**, *10*, 3336–3341. [CrossRef]
- 51. Ismail, M.; Schroeder, L.; Frese, M.; Kottke, T.; Hollmann, F.; Paul, C.E.; Sewald, N. Straightforward regeneration of FADH2 required for enzymatic tryptophan halogenation. *ACS Catal.* **2019**, *9*, 1389–1395. [CrossRef]
- 52. Payne, J.T.; Andorfer, M.C.; Lewis, J.C. Regioselective arene halogenation using the FAD-dependent halogenase RebH. *Angew. Chem. Int. Ed.* **2013**, 52, 5271–5274. [CrossRef] [PubMed]
- 53. Poor, C.B.; Andorfer, M.C.; Lewis, J.C. Improving the stability and catalyst lifetime of the halogenase RebH by directed evolution. *ChemBioChem* **2014**, *15*, 1286–1289. [CrossRef] [PubMed]

Catalysts 2019, 9, 1030 19 of 20

54. Schnepel, C.; Minges, H.; Frese, M.; Sewald, N. A High-Throughput Fluorescence Assay to Determine the Activity of Tryptophan Halogenases. *Angew. Chem. Int. Ed.* **2016**, *55*, 14159–14163. [CrossRef] [PubMed]

- 55. Minges, A.H.; Schnepel, C.; Böttcher, D.; Weiß, M.S.; Sproß, J.; Bornscheuer, U.T. Targeted Enzyme Engineering Unveiled Unexpected Patterns of. *ChemCatChem* **2019**. [CrossRef]
- 56. Frese, M.; Guzowska, P.H.; Voß, H.; Sewald, N. Regioselective Enzymatic Halogenation of Substituted Tryptophan Derivatives using the FAD-Dependent Halogenase RebH. *ChemCatChem* **2014**, *6*, 1270–1276.
- 57. Shepherd, S.A.; Karthikeyan, C.; Latham, J.; Struck, A.W.; Thompson, M.L.; Menon, B.R.K.; Styles, M.Q.; Levy, C.; Leys, D.; Micklefield, J. Extending the biocatalytic scope of regiocomplementary flavin-dependent halogenase enzymes. *Chem. Sci.* **2015**, *6*, 3454–3460. [CrossRef]
- 58. Payne, J.T.; Poor, C.B.; Lewis, J.C. Directed Evolution of RebH for Site-Selective Halogenation of Large Biologically Active Molecules. *Angew. Chem. Int. Ed.* **2015**, *54*, 4226–4230. [CrossRef]
- 59. Lang, A.; Polnick, S.; Nicke, T.; William, P.; Patallo, E.P.; Naismith, J.H.; Van Pée, K.H. Changing the regioselectivity of the tryptophan 7-halogenase PrnA by site-directed mutagenesis. *Angew. Chem. Int. Ed.* **2011**, *50*, 2951–2953. [CrossRef]
- 60. Shepherd, S.A.; Menon, B.R.K.; Fisk, H.; Struck, A.; Levy, C.; Leys, D.; Micklefield, J. A Structure-Guided Switch in the Regioselectivity of a Tryptophan Halogenase. *ChemBioChem* **2016**, *17*, 821–824. [CrossRef]
- 61. Andorfer, M.C.; Park, H.J.; Vergara-Coll, J.; Lewis, J.C. Directed evolution of RebH for catalyst-controlled halogenation of indole C–H bonds. *Chem. Sci.* **2016**, *7*, 3720–3729. [CrossRef]
- 62. Moritzer, A.-C.; Minges, H.; Prior, T.; Frese, M.; Sewald, N.; Niemann, H.H. Structure-based switch of regioselectivity in the flavin-dependent tryptophan 6-halogenase Thal. *J. Biol. Chem.* **2019**, 2529–2542. [CrossRef] [PubMed]
- 63. Payne, J.T.; Butkovich, P.H.; Gu, Y.; Kunze, K.N.; Park, H.J.; Wang, D.S.; Lewis, J.C. Enantioselective Desymmetrization of Methylenedianilines via Enzyme-Catalyzed Remote Halogenation. *J. Am. Chem. Soc.* **2018**, *140*, 546–549. [CrossRef] [PubMed]
- 64. Roy, A.D.; Grüschow, S.; Cairns, N.; Goss, R.J.M. Gene expression enabling synthetic diversification of natural products: Chemogenetic generation of pacidamycin analogs. *J. Am. Chem. Soc.* **2010**, *132*, 12243–12245. [CrossRef] [PubMed]
- 65. Runguphan, W.; Qu, X.; O'Connor, S.E. Integrating carbon-halogen bond formation into medicinal plant metabolism. *Nature* **2010**, *468*, 461–467. [CrossRef]
- 66. Glenn, W.S.; Nims, E.; Connor, S.E.O. Reengineering a Tryptophan Halogenase to Preferentially Chlorinate a Direct Alkaloid Precursor. *J. Am. Chem. Soc.* **2011**, *133*, 19346–19349. [CrossRef]
- 67. Fräbel, S.; Krischke, M.; Staniek, A.; Warzecha, H. Recombinant flavin-dependent halogenases are functional in tobacco chloroplasts without co-expression of flavin reductase genes. *Biotechnol. J.* **2016**, *11*, 1586–1594. [CrossRef]
- 68. Wang, S.; Zhang, S.; Xiao, A.; Rasmussen, M.; Skidmore, C.; Zhan, J. Metabolic engineering of Escherichia coli for the biosynthesis of various phenylpropanoid derivatives. *Metab. Eng.* **2015**, *29*, 153–159. [CrossRef]
- 69. Rudroff, F.; Mihovilovic, M.D.; Gröger, H.; Snajdrova, R.; Iding, H.; Bornscheuer, U.T. Opportunities and challenges for combining chemo- and biocatalysis. *Nat. Catal.* **2018**, *1*, 12–22. [CrossRef]
- 70. Runguphan, W.; O'Connor, S.E. Diversification of monoterpene indole alkaloid analogs through cross-coupling. *Org. Lett.* **2013**, *15*, 2850–2853. [CrossRef]
- 71. Durak, L.J.; Payne, J.T.; Lewis, J.C. Late-Stage Diversification of Biologically Active Molecules via Chemoenzymatic C-H Functionalization. *ACS Catal.* **2016**, *6*, 1451–1454. [CrossRef]
- 72. Frese, M.; Schnepel, C.; Minges, H.; Voß, H.; Feiner, R.; Sewald, N. Modular Combination of Enzymatic Halogenation of Tryptophan with Suzuki-Miyaura Cross-Coupling Reactions. *ChemCatChem* **2016**, *8*, 1799–1803. [CrossRef]
- 73. Steinkellner, G.; Gruber, C.C.; Pavkov-Keller, T.; Binter, A.; Steiner, K.; Winkler, C.; Łyskowski, A.; Schwamberger, O.; Oberer, M.; Schwab, H. Identification of promiscuous ene-reductase activity by mining structural databases using active site constellations. *Nat. Commun.* **2014**, *5*. [CrossRef] [PubMed]
- 74. Yu, H.; Yan, Y.; Zhang, C.; Dalby, P.A. Two strategies to engineer flexible loops for improved enzyme thermostability. *Sci. Rep.* **2017**, 7. [CrossRef] [PubMed]
- 75. Kellogg, E.H.; Leaver-Fay, A.; Baker, D. Role of conformational sampling in computing mutation-induced changes in protein structure and stability. *Proteins* **2011**, *79*, 830–838. [CrossRef]

Catalysts 2019, 9, 1030 20 of 20

76. Bednar, D.; Beerens, K.; Sebestova, E.; Bendl, J.; Khare, S.; Chaloupkova, R.; Prokop, Z.; Brezovsky, J.; Baker, D.; Damborsky, J. FireProt: Energy-and Evolution-Based Computational Design of Thermostable Multiple-Point Mutants. *PLoS Comput. Biol.* **2015**, *11*. [CrossRef]

- 77. Wijma, H.J.; Floor, R.J.; Jekel, P.A.; Baker, D.; Marrink, S.J.; Janssen, D.B. Computationally designed libraries for rapid enzyme stabilization. *Protein Eng. Des. Sel.* **2014**, 27, 49–58. [CrossRef]
- 78. Sun, Z.; Liu, Q.; Qu, G.; Feng, Y.; Reetz, M.T. Utility of B-Factors in Protein Science: Interpreting Rigidity, Flexibility, and Internal Motion and Engineering Thermostability. *Chem. Rev.* **2019**, *119*, 1626–1665. [CrossRef]
- 79. Andorfer, M.C.; Grob, J.E.; Hajdin, C.E.; Chael, J.R.; Siuti, P.; Lilly, J.; Tan, K.L.; Lewis, J.C. Understanding Flavin-Dependent Halogenase Reactivity via Substrate Activity Profiling. *ACS Catal.* **2017**, 7, 1897–1904. [CrossRef]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).